Human Vasodilatory Effect of GLP-1
Not Applicable
Completed
- Conditions
- Coronary StenosisAngina, StableType2 Diabetes
- Registration Number
- NCT03502083
- Lead Sponsor
- Papworth Hospital NHS Foundation Trust
- Brief Summary
Comprehensive assessment of human vasodilatory effect of GLP-1 in forearm and coronary arteries
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 11
Inclusion Criteria
- Waiting list for elective PCI to LAD Able to give informed consent Over 18
Exclusion Criteria
- GLP-1 based therapy Insulin Calcium channel blockers Nicorandil Nitrates
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Forearm bloodflow ratio with GLP-1 Change from baseline Peripheral vasodilatory response of GLP-1
Change in IMR (index of microcirculatory resistance) with GLP-1 compared with baseline Change from baseline Change in coronary microcirculatory resistance from baseline
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie GLP-1's vasodilatory effects in coronary stenosis and type 2 diabetes patients?
How does GLP-1 receptor activation compare to standard anti-anginal therapies in improving coronary blood flow?
Which biomarkers correlate with GLP-1-induced vasodilation in forearm and coronary arteries of stable angina patients?
What adverse events are associated with GLP-1 vasodilation in diabetic patients with coronary artery disease?
Are there synergistic effects when combining GLP-1 agonists with nitrates or calcium channel blockers for angina management?